Business
GB Sciences Builds Broad Cannabis Patent Portfolio -- CFN Media
GB Sciences Builds Broad Cannabis Patent Portfolio -- CFN Media.
About this update from Gb Sciences, Inc.
[{"type":"text","content":"\n \n \n GB Sciences Builds Broad Cannabis Patent Portfolio -- CFN Media\n \n \nGB Sciences Builds Broad Cannabis Patent Portfolio -- CFN Media\n \n SEATTLE, WA--(Marketwired - Jun 16, 2017) - CFN Media Group (\"CannabisFN\"), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article and interview with CEO John Poss, discussing GB Sciences Inc. (OTCQB: GBLX) and its drug development pipeline for novel cannabis-based therapies.\n Researchers have only scratched the surface of the medical value of cannabinoids as federal regulations are relaxed. While GW Pharmaceuticals plc's epilepsy programs are well-known, cannabinoids could also play a role in mitigating or reversing the effects of neurological disorders, inflammatory diseases, and hundreds of other areas. \n Competitive Advantages\n GB Sciences has several advantages over competitors ranging from its unique access to source materials to its efficient clinical discovery platform to its choice in patient populations.\n The company began by selecting patient groups based on the current standard of care, the response of disease processes to cannabinoids, and the precedent for preclinical work needed to develop these therapies in FDA-sanctioned clinical trials. The goal is to develop therapeutics targeting patient groups that aren't being helped by other companies, while accelerating the time-to-market to deliver near-term shareholder value.\n After identifying a patient population, the company's team of highly proficient scientists works to create a single elegant solution for the disease's problem set. The Network Pharmacology Platform and a high-throughput screening process helps to rapidly analyze thousands of potential combinations using cell-based models. This approach of working \"smarter, not harder\" helps keep costs low and maximizes the likelihood of success.\n Finally, the company's licenses to grow, extract, and sell cannabis under state-regulated programs enables it to produce its own standardized raw materials for use in its R&D and clinical products. The company's R&D team has pioneered tissue-culture propagation techniques to reduce genetic drift in cannabis plants, while automated, controlled growing environments help standardize the production of active ingredients.\n Numerous Programs\n GB Sciences ha...